XARACOLL Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Xaracoll patents expire, and when can generic versions of Xaracoll launch?
Xaracoll is a drug marketed by Innocoll Pharms and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-six patent family members in fifteen countries.
The generic ingredient in XARACOLL is bupivacaine hydrochloride. There are twelve drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xaracoll
A generic version of XARACOLL was approved as bupivacaine hydrochloride by HOSPIRA on February 17th, 1986.
Summary for XARACOLL
International Patents: | 26 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 123 |
Clinical Trials: | 4 |
Patent Applications: | 4,320 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in XARACOLL? | XARACOLL excipients list |
DailyMed Link: | XARACOLL at DailyMed |

Recent Clinical Trials for XARACOLL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Premier Research Group plc | Phase 3 |
Cmed | Phase 3 |
Innocoll | Phase 3 |
Pharmacology for XARACOLL
Drug Class | Amide Local Anesthetic |
Physiological Effect | Local Anesthesia |
Anatomical Therapeutic Chemical (ATC) Classes for XARACOLL
US Patents and Regulatory Information for XARACOLL
XARACOLL is protected by one US patents and one FDA Regulatory Exclusivity.
Patents protecting XARACOLL
Drug delivery device for providing local analgesia, local anesthesia or nerve blockage
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION
FDA Regulatory Exclusivity protecting XARACOLL
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Innocoll Pharms | XARACOLL | bupivacaine hydrochloride | IMPLANT;IMPLANTATION | 209511-001 | Aug 28, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Innocoll Pharms | XARACOLL | bupivacaine hydrochloride | IMPLANT;IMPLANTATION | 209511-001 | Aug 28, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XARACOLL
See the table below for patents covering XARACOLL around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Ireland | 20070220 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | ⤷ Try a Trial |
Spain | 2582368 | ⤷ Try a Trial | |
Germany | 202008018583 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |